

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/062389 A1

(51) International Patent Classification⁷: A23L 1/30, 1/305

(21) International Application Number:
PCT/EP2004/000066

(22) International Filing Date: 8 January 2004 (08.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2003A000036 13 January 2003 (13.01.2003) IT

(71) Applicant (for all designated States except US): **HUNZA
DI PISTOLESI ELVIRA & C. S.A.S.** [IT/IT]; Via Gavirate,
7, I-20148 Milano (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PISTOLESI, Elvira**
[IT/IT]; Via Gavirate, 7, I-20148 Milano (IT).

(74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND OPTION-
ALLY TRYPTOPHAN AND/OR PHYTOL DERIVATIVES

(57) Abstract: Disclosed are pharmaceutical and dietetic compositions and/or functional foods containing oils and/or phospholipids rich in polyunsaturated acids (such as α -linolenic acid, γ -linolenic acid, di-oxo- γ -linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, etc.) to which at least one of the following two molecular species is added: A) one or more indole derivatives of tryptophan and B) one or more metabolic derivatives of phytol. These preparations have revealed an unexpected, surprising synergy in preventing the bio-physiological signals of aging *in vivo* and improving the clinical parameters of the associated dysmetabolic disorders.

WO 2004/062389 A1

**PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS,
MONOTERPENES AND OPTIONALLY TRYPTOPHAN AND/OR PHYTOL
DERIVATIVES**

This invention relates to pharmaceutical or dietetic compositions containing phospholipids enriched in polyunsaturated fatty acids, mono-terpenes and at least one tryptophan and/or phytol derivative.

It has long been known that the administration with the diet of suitable
5 doses of polyunsaturated acids, such as eicosapentaenoic acid, docosahexanoic acid, α -linoleic acid, γ -linolenic acid, di-homo- γ -linolenic acid, etc., is a useful adjuvant to therapies designed to prevent and/or treat aging and the numerous dysmetabolic disorders that often accompany it.

These polyunsaturated fatty acids are administered in the form of oils
10 (which contain them in the form of tri-, di- and monoglycerides, ester derivatives and free fatty acids) or phospholipids constituted by one or more molecular species, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, phosphatidic acid, mono- and dimethylphosphatidylethanolamine and their lysoderivatives.

15 Preferred sources of these polyunsaturated acids are: a) vegetable oils (olive, soya, corn, rice, sunflower, wheat germ, borage, evening primrose, linseed, etc.); b) marine oils (cod, tuna, shark, seal, krill, etc.); c) phospholipids of animal and/or plant origin (egg, soya, oats, seaweed, etc.); and d) phospholipids obtained by chemical and/or enzymatic synthesis.

20 It has now been found that the properties of polyunsaturated acids, either in free form or in form of phospholipids, is improved, particularly bioavailability, stability and organoleptic properties, by combining them with mono-terpenes and optionally with one or more tryptophan and/or phytol derivatives.

The invention therefore provides, according to a first embodiment,

CONFIRMATION COPY

compositions comprising phospholipids enriched in polyunsaturated fatty acids, mono-terpenes and optionally one or more tryptophan and/or phytol derivatives.

The invention also provides emulsions containing inverted micelles of
5 said phospholipids, monoterpenes and optionally one or more tryptophan and/or phytol derivatives in vegetable or marine oils.

The invention also refers to a process for the preparation of said oily emulsions containing inverted micelles.

The term "phospholipids enriched in polyunsaturated fatty acids" refers
10 to phospholipids having at least 40%, preferably at least 80% and more preferably at least 90% of the acyl residues of the above mentioned polyunsaturated fatty acids.

The term "inverted micelles" has a definite meaning in the art and refers
15 anyhow to aggregates wherein the hydrophilic, polar groups of the phospholipids are concentrated in the interior and the lipophilic groups extend towards and into the oily solvent.

The monoterpenes are preferably selected from d-limonene, γ -terpinene, thymol, carvacrol, p-cymene, β -carophyllene, sabinene, borneol, carveol, eugenol, eugenol acetate, menthol, pinene, β -pinene, rosemaric acid.

20 Essential oils comprising a mixture of said monoterpenes are preferably used.

The tryptophan derivative is preferably selected from tryptophan, 5-hydroxytryptophan, melatonin, 3-indoleacetic acid, 3-indolepropionic acid, 3-indolebutyric acid, 3-indolepyruvic acid, 3-indolecarbinolic acid and
25 organic and inorganic salts thereof compatible with human and animal diets. Tryptophan and melatonin are particularly preferred.

The phytol derivative is preferably selected from phytol, phytanic acid, phytenic acid, pristanic acid, their esters (phospholipids, glycolipids, di- or

triglycerides) and their organic and inorganic salts compatible with human and animal diets. Phytol and phytanic acid are particularly preferred.

The compositions and emulsions of the invention preferably contain both the tryptophan and the phytol derivative, as defined above.

5 The preparation of the oily emulsions can be obtained with the following procedure:

- a) the phospholipid(s), the phytol- and the tryptophan -derivative(s) are co-dissolved in an organic, apolar solvent(s). After a mild agitation at room temperature, the solvent(s) is then evaporated
10 under vacuum to obtain a powder of the co-mixed phospholipid(s), phytol- and indole-derivative(s).
- b) The essential oil(s) containing the monoterpene(s) are sprayed on this powder a) maintained in suspension through the influx of a strong air current.
- 15 c) The sprayed powder b) is then dissolved, under mild agitation at room temperature, into the polyunsaturated oil(s). In few minutes a polyunsaturated oily emulsion containing the "inverted micelles" of phospholipid(s), monoterpene(s), phytol- and indole-derivative(s) is so obtained.

20 Preferred sources of monoterpenes, tryptophan and phytol derivatives are suitable purified fractions of extracts of animal and/or plant origin obtainable by known methods; alternatively, they can be obtained by known chemical and/or enzymatic synthesis.

25 Polyunsaturated fatty acids (in the form of phospholipids and/or oils that contain them) are present in the compositions of the invention in such quantities as to provide doses ranging between 0.1 and 2000 mg, and preferably 10 to 200 mg/day/kg of body weight of the patient treated.

The monoterpenes are present in the compositions of the invention in

such amounts as to provide doses ranging from 0.015 to 15, preferably from 0.1 to 3.0 mg/day/kg of body weight of the patient treated.

Tryptophan derivatives are present in the compositions of the invention in such quantities as to provide doses ranging between 0.001 and 50 mg, and
5 preferably 0.05 to 5.0 mg/day/kg of body weight of the patient treated.

Phytol derivatives are present in the compositions of the invention in such quantities as to provide doses ranging between 0.005 and 50 mg, and preferably 0.2 to 20.0 mg/day/kg of body weight of the patient treated.

The compositions according to the invention can also contain other
10 known nutritional constituents which further enhance their properties and therapeutic benefits.

Examples of these possible additional constituents are:

- a) vitamins and vitamin-like factors with antioxidant activity, such as vitamin E and vitamin C and derivatives thereof; β -carotenes;
15 vitamin A; vitamin D; lipoic acid; coenzyme Q; etc.
- b) extracts of medicinal plants or vegetables based on simple polyphenols or flavonoids of different kinds; diterpenes; saponins; phytosterols; etc.
- c) proteins, peptides or aminoacids and their derivatives such as
20 glutathione, carnosine, carnitine, creatine, taurine, arginine, etc.
- d) nucleic acids; oligonucleotides; nucleotides; nucleosides and the nitrogenous bases contained in them.
- e) mineral salts and trace elements such as Mg; Ca; Zn; Se; Va; Cr; K; Na; etc.
- 25 f) yeasts, milk enzymes and extracts or purified fractions thereof (for example red yeast extracts such as "Monascus Ruber", titrated and standardised in Monacolina K).

Oils and phospholipids with the addition of suitable monoterpenes,

tryptophan and phytol derivatives according to the invention can be used to enrich functional foods of a lipid nature (condiment oils, margarine, butter, mayonnaise, mustard, chocolate, etc.) or to make pharmaceutical preparations, preferably contained in hard or soft gelatine capsules. Alternatively, these oils
 5 and/or phospholipids with additions according to the invention can be sprayed onto protein media (proteins and/or peptides of plant or animal origin) or polysaccharide media (starches, cellulose, animal or plant fibres of different kinds, etc.) to obtain water-dispersible powders or granulates of a lipoprotein or liposaccharide nature respectively. These powders or granulates can be
 10 used to enrich functional foods (such as bread, pasta, bakery products, milk and derivatives, sausages, foods based on meat and fish, various types of drinks, etc.) or to make galenical preparations (such as tablets, capsules, dragées, cachets, etc.), mixed with conventional excipients.

Oils and/or phospholipids with additions according to the invention can
 15 also be used to make cosmetic preparations designed for topical use (such as lotions, creams, ointments, etc.) for the treatment or prevention of skin aging processes, alopecia, cellulitis and the like.

The invention is illustrated in detail in the examples set out below.

Example 1

20	a) Phosphatidylserine (Ph-Ser) obtained enzymatically from soya lecithins (degree of purity $\geq 90\%$)	80 g
	+ b) Fractions enriched with marine oil docosahexaenoic acid (DHA) (DHA = 80%)	600 g
	+ c) Melatonin	1 g
25	+ d) Phytanic acid	25 g
	+ e) Essential oily mixture containing monoterpenes (d-limonene, γ -terpinene, thymol, etc..)	2 g

Phosphatidylserine (a), melatonin (c) and phytanic acid (d) are co-dissolved in 20 vol. of chloroform-methanol (2:1, by vol.). The solvents are

then evaporated under vacuum to obtain a co-mixed powder of (a)+(c)+(d). The essential oily mixture of monoterpenes (e) is sprayed on this co-mixed powder of (a)+(c)+(d). The sprayed powder is slowly dissolved, under mild agitation, into the marine oil (b). A marine oil emulsion containing the "inverted micelles" of phosphatidylserine, phytanic acid, melatonin and monoterpenes is so obtained.

Example 2

- | | | | |
|----|------|--|--------|
| | a) | Soya lecithins with a high content of Ph-Ser (Ph-Ser = 20%) | 14 g |
| 10 | + b) | Oily mixture of olive oil (80%) and marine oils (20%), the latter containing 18% DHA and 12% eicosapentaenoic acid (EPA) | 1000 g |
| | + c) | Tryptophan | 9 g |
| | + d) | Melatonin | 0.03 g |
| | + e) | Phytol | 6 g |
| 15 | + f) | Essential oily mixture containing monoterpenes (d-limonene, γ -terpinene, thymol, etc..) | 4 g |

The olive and marine oil emulsion containing the "inverted micelles" of phosphatidylserine, tryptophan, melatonin, phytol and monoterpenes is prepared according to the procedure described in Example 1.

Example 3

- | | | | |
|----|------|--|---------|
| 20 | a) | Oily mixture of olive oil (85%) and marine oils (15%), the latter containing 12% DHA and 24% EPA | 1000 g |
| | + b) | Soya lecithins with a high content of phosphatidylcholine (Ph-choline \geq 85%) | 4 g |
| | + c) | Melatonin | 0.001 g |
| 25 | + d) | Phytol | 4.5 g |
| | + e) | Essential oily mixture containing monoterpenes (d-limonene, γ -terpinene, thymol, etc..) | 2 g |

The olive and marine oil emulsion containing the "inverted micelles" of phosphatidylcholine, melatonin, phytol and monoterpenes is prepared according to the procedure described in Example 1.

Example 4

- | | | |
|----|--|---------|
| | a) Rice oil containing tri- and diglycerides (the latter $\geq 40\%$) | 1000 g |
| 5 | + b) Soya lecithins containing phosphatidylcholine (40%),
phosphatidylethanolamine (30%), phosphatidylinositol (15%),
phosphatidylserine (2%) and phosphatidic acid (2%) | 5 g |
| | + c) Melatonin | 0.001 g |
| | + d) Phytol | 5 g |
| | + e) Essential oily mixture containing monoterpenes
(d-limonene, γ -terpinene, thymol, etc..) | 2 g |
| 10 | The rice oil emulsion containing the "inverted micelles" of
phospholipids, melatonin, phytol and monoterpenes is prepared according to
the procedure described in Example 1. | |

Example 5

- | | | |
|----|---|-------|
| 15 | a) Phosphatidylglycerol (PhG) obtained by enzymatic method
from soya lecithins (degree of purity $\geq 90\%$) | 80 g |
| | + b) 50% of linseed oil with an α -linolenic acid content of $\geq 55\%$
and 50% of purified marine oil with an
eicosapentaenoic acid content $\geq 50\%$ | 600 g |
| | + c) Melatonin | 0.5 g |
| 20 | + d) Phytol | 5 g |
| | + e) Essential oily mixture containing monoterpenes
(d-limonene, γ -terpinene, thymol, etc..) | 5 g |
| 25 | The linseed and marine oil emulsion containing the "inverted micelles"
of phosphatidylglycerol, melatonin, phytol and monoterpenes is prepared
according to the procedure described in Example 1. | |

Example 6

- | | | |
|----|---|-------|
| | a) Phosphatidylinositol (PhI) obtained by purification from
soya lecithins (degree of purity $\geq 90\%$) | 100 g |
| | + b) Enriched fractions of marine oil EPA (EPA $\geq 80\%$) | 600 g |
| 30 | + c) Melatonin | 1 g |
| | + d) Phytanic acid | 25 g |

- + e) Essential oily mixture containing monoterpenes
(d-limonene, γ -terpinene, thymol, etc..) 5 g

The marine oil emulsion containing the "inverted micelles" of phosphatidylinositol, melatonin, phytanic acid and monoterpenes is prepared according to the procedure described in Example 1.

Example 7

- a) Soya lecithins with a high content of phosphatidic acid ($\geq 60\%$) 100 g
- 10 + b) 50% Linseed oil with an α -linolenic acid content $\geq 55\%$
and 50% of purified marine oil with an eicosapentaenoic
and docosahexapentaenoic acid content $\geq 20\%$ 600 g
- + c) Melatonin 10 g
- + d) Phytanic acid 25 g
- 15 + e) Essential oily mixture containing monoterpenes
(d-limonene, γ -terpinene, thymol, etc..) and flavours 25 g

The linseed and marine oil emulsion containing the "inverted micelles" of phosphatidic acid, melatonin, phytanic acid and monoterpenes is prepared according to the procedure described in Example 1. This emulsion is preferably formulated for topical (cosmetic) use (for the treatment of alopecia, cellulite, skin aging, etc..).

Example 8

- a) Soya phosphatidylcholine 900 g
- + b) Green tea bioflavones with a high epigallocatechin-gallate content ($\geq 45\%$) 150 g
- 25 + c) Marine oil containing 12% DHA, 24% EPA and 0,4% of
essential oily mixtures containing monoterpenes
(d-limonene, thymol, etc..) 900 g
- + d) Melatonin 1 g
- + e) Phytanic acid 20 g

30 Phosphatidylcholine is dissolved in hot ethanol and mixed with green tea bioflavones dissolved in ethanol. The ethanol solvent is evaporated and the granulate of bioflavones and phosphatidylcholine thus obtained is dissolved

slowly, under stirring, in the oily solution constituted by compounds c) + d) + e). The marine oily emulsion which forms and contains the "inverted micelles" of phosphatidylcholine, bioflavones, melatonin and phytanic acid is used to prepare soft capsules, each containing 1 g of the micellar emulsion.

5 **Example 9**

	a) Soya lecithins with as reported in Example 4 b)	10 g
	+ b) Lyophilised yeasts (<i>Saccharomyces</i>)	50 g
	+ c) Essential oily mixture containing monoterpenes (d-limonene, γ -terpinene, thymol, etc..)	0.5 g
10	+ d) Melatonin	0.001 g
	+ e) Phytol	0.5 g

The essential oily mixture containing monoterpenes, melatonin and phytol are sprayed on the powder of lyophilized yeasts. The sprayed powder is then co-mixed with the lecithins and used to prepare sachets, each containing
15 7 g of these co-mixed powders.

PHARMACOLOGICAL AND/OR DIET THERAPY TESTS

In all the pharmacological and diet therapy tests conducted on animals and men, the effects obtainable with the administration of the oily emulsions, containing the "inverted micelles" of phospholipids with the additions
20 according to the invention, have always proved highly significant, and in any event far superior to those obtained with the administration of similar doses of polyunsaturated oils and/or phospholipids alone, both in preventing the biological signs of aging (improved mitochondrial activity, improved membrane fluidity, improved antioxidant defences in the plasma and tissues,
25 limitation and reduction of excess weight) and improving the clinical parameters tested for the prevention of aging and many of the associated dysmetabolic disorders: obesity and overweight, atherosclerosis, diabetes, hypertension, dyslipidaemia, Alzheimer's disease, Parkinson's disease, senile

dementia, osteoporosis, mental and physical stress, depression, menopausal disorders, prostate hypertrophy, skin aging, alopecia, etc.

CLAIMS

1. Compositions comprising phospholipids enriched in polyunsaturated fatty acids, mono-terpenes and at least one or more tryptophan and/or phytol
5 derivatives.
2. Compositions as claimed in claim 1, wherein the polyunsaturated acids are selected from: eicosapentaenoic acid, docosahexanoic acid, α -linoleic acid, γ -linolenic acid and di-oxo- γ -linolenic acid.
3. Compositions as claimed in claim 1 or 2, containing vegetable or
10 marine oils.
4. Compositions as claimed in claim 3 in form of emulsions containing inverted micelles.
5. Compositions as claimed in one or more of claims 1 to 4 wherein the monoterpenes are selected from d-limonene, γ -terpinene, thymol, carvacrol,
15 p-cymene, β -carophyllene, sabinene, borneol, carveol, eugenol, eugenol acetate, menthol, pinene, β -pinene, rosemaric acid.
6. Compositions as claimed in one or more of claims 1 to 5, wherein the tryptophan derivatives are selected from tryptophan, 5-hydroxytryptophan, melatonin, 3-indoleacetic acid, 3-indolepropionic acid, 3-indolebutyric acid,
20 3-indolepyruvic acid and 3-indolecarbinolic acid.
7. Compositions as claimed in one or more of claims 1 to 6, wherein the phytol derivatives are selected from phytol, phytanic acid, phytenic acid, pristanic acid, their esters (phospholipids, glycolipids, di- or triglycerides) and their organic and inorganic salts compatible with human and animal diets.
- 25 8. Compositions as claimed in one or more of claims 1 to 7, in the form of hard or soft gelatin capsules, water-dispersible lipoprotein or liposaccharide powders, topical formulations, or food additives.
9. Compositions as claimed in one or more of claims 1 to 8, also

containing suitable excipients and/or nutritional components.

10. A process for the preparation of the emulsions comprising inverted micelles of claim 4, which comprises:

- a) dissolving the phospholipid(s), the phytol and tryptophan derivative(s) in organic apolar solvents, followed by solvent evaporation;
- b) spraying the essential oil(s) containing the monoterpene(s) on the powder obtained in a);
- c) dissolving the sprayed powder in the polyunsaturated oil(s).

10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 2004/000066A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23L1/30 A23L1/305

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A23L A23J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, FSTA, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/48386 A (STUECKLER FRANZ) 30 September 1999 (1999-09-30) claims 1,3,7,13; examples 1,2	1-3,5, 7-9
A	WO 02/052955 A (HUNZA DI PISTOLESI ELVIRA E C ; PISTOLESI ELVIRA (IT)) 11 July 2002 (2002-07-11) the whole document	1-10
A	US 5 434 183 A (LARSSON-BACKSTROEM CARIN) 18 July 1995 (1995-07-18) claims	1
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

15 June 2004

Date of mailing of the international search report

30/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lepretre, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/000066

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE FSTA 'Online! INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANKFURT-MAIN, DE; MARIANI C ET AL: "Structure of olive oil waxes." XP002284545 Database accession no. 2003-00-n0037 abstract & RIVISTA ITALIANA DELLE SOSTANZE GRASSE, vol. 79, no. 3, 2002, pages 49-57, MILAN, ITALY</p> <p style="text-align: center;">-----</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/000066

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9948386	A	30-09-1999	AT 407821 B	25-06-2001
			AT 52598 A	15-11-2000
			WO 9948386 A1	30-09-1999
			AU 2911399 A	18-10-1999
			CA 2325437 A1	30-09-1999
			EP 1065946 A1	10-01-2001
			US 6605296 B1	12-08-2003
WO 02052955	A	11-07-2002	IT MI20002854 A1	01-07-2002
			WO 02052955 A1	11-07-2002
			EP 1345501 A1	24-09-2003
			US 2004052922 A1	18-03-2004
US 5434183	A	18-07-1995	AT 216227 T	15-05-2002
			AU 657969 B2	30-03-1995
			AU 1910192 A	08-01-1993
			CA 2109611 A1	10-12-1992
			DE 69232564 D1	23-05-2002
			DE 69232564 T2	26-09-2002
			EP 0660708 A1	05-07-1995
			ES 2174833 T3	16-11-2002
			IE 921477 A1	02-12-1992
			JP 3387498 B2	17-03-2003
			JP 6508123 T	14-09-1994
			NZ 242697 A	25-02-1994
			PT 100524 A ,B	31-08-1993
			WO 9221335 A1	10-12-1992
			SG 64864 A1	16-01-2001